tbuckley/cabot-search huggingface dataset:
Metabolism of Orally Administered Cadmium-Metallothionein in Mice
Authors: M. George Cherian
Journal: Environmental Health Perspectives (1979)

The main source of cadmium in the diet is cereal or meat, especially in liver and kidney. Since the cadmium in both liver and kidney is bound to metallothionein, a heat-stable protein, the gastrointestinal absorption and metabolism of cadmium metallothionein (CdMt) was studied in detail. The selective renal cadmium deposition after oral CdMt was analogous to the studies on injected CdMt. Metallothionein with 109Cd or 35S-cysteine radioactive label was isolated from rat liver and administered orally (60 microgram Cd) through a gastric tube to mice (C57 BL/6J). After 4 hr, a major portion of the ingested CdMt was isolated intact from intestinal mucosal cells. However, only a small amount of cadmium bound metallothionein was present in the kidney supernatant. The protein moeity was also degraded completely in kidney. The absorption and tissue distribution of cadmium from oral-cysteine and cadmium-glutathione complexes were similar to that after oral CdCl2 in mice. These results that oral CdMt may be absorbed intact from the gastrointestinal tract and the protein is degraded during renal deposition.
Respiratory Depression
Authors: C. G. Blakeley
Journal: BMJ (1948)

<h3>Abstract</h3> <h3>Background and Aims</h3> The xenobiotic nuclear receptor Constitutive Androstane Receptor (CAR) is essential for xenobiotic tumor promotion in mouse models. In these models, β-catenin is genetically activated in approximately 80% of tumors. Chronic Hepatitis B Virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC), and β-catenin activation is also frequently activated in HBV-associated HCCs. The goal of this research was to determine whether activation of CAR in a mouse model of chronic HBV infection would result in tumor formation and whether these tumors would display increased β-catenin activation. <h3>Approach and Results</h3> We treated transgenic mice expressing the HBV X protein (HBx) in hepatocytes with a single dose of the potent CAR agonist TCPOBOP. After 10 months, these mice developed large liver tumors that are characterized by β-catenin nuclear localization and upregulation of β-catenin targets. The β-catenin regulator FoxM1 and the oxidative stress master regulator Nrf2, both of which are CAR gene targets, were also overactivated in tumors. The CAR/HBx tumors share a conserved gene signature with HBV-related human hepatocellular carcinoma. <h3>Conclusions</h3> Activation of CAR in the presence of HBx results in tumors with strong β-catenin activation. The mouse model we have described reflects the gene expression patterns seen in human HBV-associated HCC and presents an attractive basis for future studies.
Abstract 91: Useful Predictor of Responsiveness to Initial Intravenous Immunoglobulin in Kawasaki Disease
Authors: jihee kwak
Journal: Circulation (2015)

Background and Objectives: Ten to twenty percent of children with Kawasaki disease (KD) do not respond to initial intravenous immunoglobulin (IVIG) treatment, and if untreated approximately 15% to 25% of patients with KD have complications. The aim of our study is to find more useful predictors of responsiveness to initial IVIG in KD. Subjects and Methods: We retrospectively reviewed medical records of 91 children diagnosed with KD at Myong Ji Hospital from March 2012 to April 2014. Laboratory data obtained before and 24 to 36 hours after IVIG treatment were collected, which include hemoglobin level, white blood cell count, proportions of neutrophils, lymphocytes and eosinophils, platelet count, erythrocyte sedimentation rate, C-reactive protein (CRP), creatine kinase (CK), creatine kinase MB (CK-MB) and N[[Unsupported Character - Codename &amp;shy;]]terminal pro-brain natriuretic peptide (NT-proBNP). Subjects were then divided in to 2 groups, IVIG-responsive and IVIG-resistant. Results: Among the 91 patients, 11 patients (12%) required retreatment. By univariate analysis, before-IVIG laboratory parameters of white blood cell count, % neutrophils, erythrocyte sedimentation rate, CRP, sodium, CK, CK-MB and NT[[Unsupported Character - Codename &amp;shy;]]proBNP were significantly different. In the after-IVIG laboratory parameters, hemoglobin level, white blood cell count, % neutrophils, % lymphocytes, CRP, CK, CK-MB and NT-proBNP were significantly different. While the mean-differences were not statistically significant, fractional change (FC)-CRP and FC-% neutrophils showed significant difference. By multivariate analysis, FC-CRP was confirmed to be an independent predictor for initial IVIG resistance. Conclusion: FC-CRP might be a more useful and important value for predicting initial IVIG responsiveness in KD patients than before- and after-IVIG CRP.
Abstract 314: Inactivation-Resistant GSK3αβ Dual Isoform Expression Attenuates Isoproterenol-Induced Myocardial Hypertrophy and Preserves Cardiac Function
Authors: Ian G Webb, Yasuhiro Nishino, James E Clark, Colin E Murdoch, Ajay M Shah, Michael S Marber
Journal: Circulation (2008)

Glycogen synthase kinase-3 (GSK-3) is implicated as an important signalling mediator in normal developmental myocardial growth and adverse hypertrophic remodelling. Upstream phosphorylation of isoform specific N-terminal serine residues - ser21(GSK-3α) and ser9(GSK-3β), respectively - inhibits kinase activity. Opposing effects of the two isoforms have recently been described in response to hypertrophic stimuli, but little is known of the overall effect of dual-isoform manipulation. We set out to characterise baseline and isoproterenol (ISO) stimulated phenotypes of mice with inactivation-resistant GSK-3αβ knockin (KI) alleles, in which ser21/9 are converted to non-phosphorylatable alanine. Between 5–15 weeks there was a non-significant trend towards higher heart weight (HW): body weight (BW) ratios in KI mice versus wild type (WT) mice. Mean left ventricular wall thickness (LVWT) at the level of the papillary muscle was comparable between genotypes (1.3±0.2mm vs 1.6±0.2mm, ns, n=8). 8–10 week old weight-matched mice received 2 weeks subcutaneous ISO (30mg/kg/d) or control saline (Con) infusions. WT hearts hypertrophied with ISO (LVWT 1.9±0.1mm vs 1.3±0.2mm Con, n=8; HW:BW ratio 6.7±0.6 vs 5.4±0.4 Con, n=10, both p&lt; 0.05), but KI mice did not (1.4±0.1mm vs 1.6±0.2mm KI Con; HW:BW 6.2±1.0 vs 6.1±0.6 KI Con, respectively, both ns). Hypertrophy in the WT hearts was associated with reduced LV ejection fraction (41±9% vs 63±5% Con, n=6, p&lt; 0.05) and greater interstitial fibrosis (2.1±0.5% vs 0.8±0.6%, n=6, p&lt; 0.05). These were both attenuated in the KI mice subjected to ISO (70±13% vs 64±11% Con, and 1.3±0.7% vs 0.8±0.3% Con, respectively, both ns). GSK-3 inhibition with daily intraperitoneal 6-bromoindirubin-3′-oxime restored hypertrophic sensitivity to ISO in the KI mice (LVWT 1.8±0.2mm; HW:BW 7.3±0.5, p&lt; 0.05 for both groups vs KI + ISO alone) but had no effect in the absence of hypertrophic stimulus (1.4±0.2mm and 5.4±0.7, respectively, for KI + Con + Bio, ns vs KI + Con alone). In conclusion, inactivation-resistant GSK-3αβ dual isoform expression does not affect age-related (eutrophic) myocardial growth in the mouse. However, it protects against pathological growth, maintaining cardiac function and attenuating interstitial fibrosis.
MAISTER PETER LOWE (c 1550-1610)
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Belt tightening at the NIH. Just how alarming is the alarm?
Authors: A. Blum
Journal: JAMA (1980)

SHOULD cost containment, an increasingly prominent consideration in clinical medicine, be applied equally to biomedical research? Or ought publicly financed research be shielded in some way from economic constraints, not to mention political and social pressures? As an alarm is sounded<sup>1</sup>over proposed cutbacks in allocations to the National Institutes of Health (NIH), it is necessary for physicians and other members of the health care field to seek answers to these questions. Such scrutiny may affront many researchers who rightly see themselves as devoted workers and innocent bystanders (or victims) of political tugs-of-war. Indeed, scientists at the NIH and many "alumni" throughout the country have every reason to be proud of their investigations into the cause, detection, therapy, and prevention of disease. To call the NIH the foremost biomedical research center in the world is an understatement. Even the casual visitor to its campus shares the excitement and privilege of
KEYNOTE-062: Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Authors: Josep Tabernero, Yung-Jue Bang, Charles S. Fuchs, Atsushi Ohtsu, Uma Kher, Baohoang Lam, Minori Koshiji, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2016)

TPS4138 Background: Pembrolizumab (pembro) is a monoclonal antibody against PD-1 designed to block its interaction with PD-L1 and PD-L2 and permit an antitumor immune response. In KEYNOTE-012, pembro showed a 22% ORR (RECIST v1.1, central review) and manageable safety profile in patients (pts) with advanced gastric cancer. The randomized, phase 3 KEYNOTE-062 study (NCT02494583) is designed to compare the efficacy and safety of pembro alone or in combination with cisplatin + fluoropyrimidine with those of cisplatin + fluoropyrimidine as first-line therapy for PD-L1+/HER2– advanced gastric or GEJ adenocarcinoma. Methods: Key eligibility criteria include age ≥ 18 y, locally advanced/metastatic PD-L1+/HER2– gastric or GEJ adenocarcinoma, ECOG PS 0-1, no active autoimmune disease, brain metastases, or prior therapy for advanced disease. Pts are randomized 1:1:1 to pembro 200 mg Q3W (arm 1), pembro + cisplatin 80 mg/m2 Q3W + 5-fluorouracil (5-FU) 800 mg/m2 on days 1-5 of each Q3W cycle (arm 2), or placebo Q3W + cisplatin + 5-FU (arm 3); 5-FU may be replaced with capecitabine 1000 mg/m2 twice daily on days 1-14 of each cycle. Randomization is stratified by region (Europe/North America/Australia vs Asia vs rest of world), disease status (locally advanced vs metastatic), and chosen fluoropyrimidine (5-FU vs capecitabine). Arm 1 is open label; in arms 2 and 3, assignment to pembro vs placebo is double blind. All treatments will continue for 35 cycles or until progressive disease, unacceptable toxicity, or pt/investigator decision. Response will be evaluated every 6 wk per RECIST v1.1 by central imaging vendor review and per RECIST adapted for immunotherapy response patterns; eligible pts may continue treatment beyond initial RECIST-defined progression. AEs will be assessed throughout treatment and for 30 d thereafter (90 d for serious AEs) and graded per NCI CTCAE v4.0. Pts will be followed for survival every 3 mo. OS and PFS per RECIST v1.1 are the primary study end points; secondary end points include ORR and duration of response. Enrollment in KEYNOTE-062 is ongoing and will continue until ~750 pts have enrolled. Clinical trial information: NCT02494583.
IT'S MY BOOK
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>QuickStats:</i> Number of Homicides Committed, by the Three Most Common Methods* — United States, 2010–2016
Authors: Holly Pifer, Arialdi Minino, Sally Curtin, Hanyu Ni
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Su ocationYear * The three most common methods of homicide are based on numbers of deaths and are identified with International Classification of Disease, Tenth Revision (ICD-10) codes X93-X95, U01.4 (firearms), X99 (cutting/ piercing), and X91 (suffocation).During 2010-2016, use of firearms was the most common homicide method in the United States, followed by the use of instruments for cutting and piercing and then suffocation.The number of firearm-related homicides was relatively stable during 2010-2014 (fluctuating between 11,008 and 11,622) but then increased by 31% from 2014 (11,008) to 2016 (14,415).In 2016, the number of homicides involving firearms was approximately eight times the number of those involving cutting and piercing (1,781) and approximately 30 times those involving suffocation (502).
Ophthalmology
Authors: Frederick C. Blodi
Journal: JAMA (1981)

This year, significant advances have been made in both clinical and experimental ophthalmology. <h3>Treatment of Conjunctival Melanoma</h3> The treatment of diffuse malignant melanoma of the conjunctiva has been enriched by the recent experience of Jakobiec et al,<sup>1</sup>who have had excellent success using cryotherapy for two extensive areas of flat intraepithelial melanosis. They advise surgical excisions of tumefactions and invasive melanomas, but find repeated cryoapplications most suitable for controlling widespread flat disease. This method would be of great benefit because it could avoid exenteration in patients who have widespread melanotic lesions. The conjunctiva treated by cryoapplication recovers quickly after a transient phase of inflammatory reaction. The conjunctival stroma is not damaged, and normal reepithelialization can occur from adjacent zones of conjunctiva. <h3>Surgical Treatment of Myopia</h3> The surgical treatment of myopia has attracted considerable attention in the lay media. A new approach, the radical keratotomy, was introduced into the United
Rheumatism and Its Treatment by the Use of the Percusso-Punctator.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE EXCRETION OF STEROLS
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rheumatoid Disease
Authors: Benjamin K. Harris
Journal: JAMA (1976)

<h3>To the Editor.—</h3> We noted with interest the report by Goldenberg and Gibbons (235:284, 1976) of seropositive rheumatoid arthritis and HLA 27. We would interpret the clinical and laboratory studies to indicate that the patient had inflammatory bowel disease with spondylitis, and that rheumatoid arthritis subsequently developed. While it is unusual to see seropositive rheumatoid disease with nodules and few articular findings, such cases have been described.<sup>1</sup> We have recently seen a 44-year-old man with a history of Reiter syndrome diagnosed in 1961. In June 1975, he had asymmetric, painful swelling involving the wrists and the metacarpophalangeal and proximal interphalangeal joints. The patient was initially thought to have an exacerbation of Reiter syndrome, although there were no genitourinary, mucocutaneous, or ocular manifestations. He had positive reactions for HLA W27 (B27 according to the newer nomenclature), and his latex test for rheumatoid factor was positive in a dilution of 1:1,280.
HYDROCYANIC ACID ANTIDOTAL TO TUBERCULOSIS.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial.
Authors: Y. Bang, Y. W. Kim, H. Yang, H. C. Chung, Y. Park, K. Lee, K. H. Lee, Y. H. Kim, S. Noh, J. Ji, M. Johnston, F. Sirzen, S. H. Noh
Journal: Journal of Clinical Oncology (2011)

LBA4002 The full, final text of this abstract will be available in Part II of the 2011 Annual Meeting Proceedings, distributed onsite at the Meeting on June 4, 2011, and as a supplement to the June 20, 2011, issue of Journal of Clinical Oncology.
Physiopathologie des traversées chimiques et bactériennes dans l'organisme
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editors and Advertisements
Authors: Drummond Rennie
Journal: JAMA (1991)

Drug advertisements figure heavily in clinical journals. Indeed, the inclusion of ads directed toward the prescribing physician practically defines the journals as being clinical. Such ads merit particular scrutiny because the person they try to reach, the physician, is not the one who has to pay for the product. Goldstein,<sup>1</sup>in a witty and perceptive Commentary, questions whether the judgment of editors of clinical journals is affected by the fact that their journals are supported in part by money paid to them by pharmaceutical companies to publish ads for drugs. He draws a parallel between the editors' acceptance of ads and physicians' accepting gifts from drug company representatives. Indeed, he gives a partial, but impressively long, list of the freebies he has himself received: not, perhaps, the best stance from which to question the practices of others, but disarmingly honest. Having concluded that there is a problem with journals,
INDIUM-lll-LABELED LEUKOCYTE IMAGING IN CLINICAL PRACTICE; THE UNUSUAL AND THE ROUTINE. AN ANALYSIS OF 125 CASES.
Authors: Daniel A. Navarro, Paul M. Weber, L. V. dos Remedios, Isamu Y. Kang
Journal: Clinical Nuclear Medicine (1983)

Navarro, Daniel A.; Weber, Paul M.; dos Remedios, L. V.; Kang, Isamu Y. Author Information